BBOT

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

BridgeBio Oncology Therapeutics, Inc.

NASDAQ | BBOT

11.39

USD

$0.00

(

0.00%

)

At Close (As of Oct 13, 2025)

-

Market Cap

-

P/E Ratio

-

EPS

$13.18

52 Week High

$8.69

52 Week Low

HEALTHCARE

Sector

BBOT Chart

Recent Chart
Price Action

BBOT Technicals

Tags:

BBOT Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$584K
Selling General And Administrative $584K
Research And Development $73M
Operating Expenses $584K
Investment Income Net -
Net Interest Income $6.4M
Interest Income $6.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $7.6M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$74M
Comprehensive Income Net Of Tax -
Ebit -
Ebitda $7.6M
Net Income $7.6M

Revenue & Profitability

Earnings Performance

BBOT Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $194M
Total Current Assets $1.9M
Cash And Cash Equivalents At Carrying Value $1.7M
Cash And Short Term Investments $1.7M
Inventory -
Current Net Receivables -
Total Non Current Assets $192M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $125M
Other Current Assets $252K
Other Non Current Assets -
Total Liabilities $5.7M
Total Current Liabilities $188K
Current Accounts Payable $3.1M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $5.5M
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $188K
Other Non Current Liabilities -
Total Shareholder Equity $189M
Treasury Stock -
Retained Earnings -$3.7M
Common Stock $192M
Common Stock Shares Outstanding $17M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$764K
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $208K
Capital Expenditures $49K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$184M
Cashflow From Financing $186M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $7.6M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$584K
Selling General And Administrative $584K
Research And Development $73M
Operating Expenses $584K
Investment Income Net -
Net Interest Income $6.4M
Interest Income $6.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $7.6M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$74M
Comprehensive Income Net Of Tax -
Ebit -
Ebitda $7.6M
Net Income $7.6M

BBOT Profile

BridgeBio Oncology Therapeutics, Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, focused on the development of targeted small molecule inhibitors designed to treat various forms of cancer. Leveraging its innovative drug discovery platform, the company aims to address unmet medical needs in oncology through precision medicine approaches. With a robust pipeline of therapeutic candidates, BridgeBio is strategically positioned to advance an array of treatments from preclinical stages to clinical trials, targeting specific genetic drivers of cancer for improved patient outcomes.

VHAI
-25.00%
$0.00
YYAI
-12.21%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
ELBM
+334.95%
$7.17
PLUG
+13.44%
$3.87
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVDA
+2.25%
$187.29
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
TSLA
+5.01%
$434.23
CLF
+5.50%
$13.90
F
+0.96%
$11.52
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
RR
+7.85%
$6.38
ACHR
+6.64%
$12.76
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
MP
+23.30%
$96.60
NAK
+26.47%
$2.56
USAR
+22.60%
$39.97
RMBL
+60.50%
$3.21
IREN
+8.04%
$64.58
ABAT
+34.34%
$9.06
ADD
-25.47%
$0.05
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
EPWK
-11.00%
$0.08
NAKA
-4.05%
$0.83
UAMY
+37.67%
$16.80
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
PFE
+0.10%
$24.80
ADAP
-0.70%
$0.18
BMNR
+7.40%
$56.35
QUBT
+10.49%
$21.01
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
CJET
-14.93%
$0.12
MRVL
-5.52%
$85.61
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
MULN
-55.00%
$0.63
BINI
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
RF
+1.84%
$24.60
QSI
+23.35%
$2.06
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
T
-1.10%
$25.58
SMR
+15.95%
$45.50
VHAI
-25.00%
$0.00
YYAI
-12.21%
$0.16
STAI
+39.44%
$0.62
CGBS
-39.47%
$0.03
BURU
+6.25%
$0.50
ELBM
+334.95%
$7.17
PLUG
+13.44%
$3.87
GWH
+149.66%
$10.38
RGTI
+20.26%
$52.82
ASST
-35.33%
$1.00
BITF
+25.47%
$5.26
IONZ
-35.04%
$2.21
BYND
-47.01%
$1.06
NVDA
+2.25%
$187.29
NVTS
+23.51%
$10.16
DNN
+6.94%
$3.07
CAN
+33.93%
$1.45
QBTS
+23.97%
$40.93
INTC
+2.03%
$37.11
GPUS
-12.50%
$0.41
WULF
-0.58%
$13.51
JOBY
+2.61%
$16.70
AXDX
-61.36%
$0.03
BBD
+1.30%
$3.10
TSLA
+5.01%
$434.23
CLF
+5.50%
$13.90
F
+0.96%
$11.52
QS
+16.36%
$17.10
CRML
+56.07%
$23.38
NIO
+6.59%
$7.15
ETHD
-11.62%
$3.37
AMD
+0.40%
$215.76
PWM
+12.50%
$1.17
RXRX
+4.41%
$5.55
CIFR
+19.77%
$20.32
LAES
+13.49%
$6.14
APLD
+2.14%
$34.71
BTBT
+5.58%
$3.97
SOFI
+4.45%
$27.35
DVLT
-12.36%
$1.66
TLRY
+0.58%
$1.73
DFLI
+41.35%
$1.54
ONDS
+18.43%
$10.92
RR
+7.85%
$6.38
ACHR
+6.64%
$12.76
SOUN
+10.77%
$19.23
WBD
-3.22%
$17.10
MP
+23.30%
$96.60
NAK
+26.47%
$2.56
USAR
+22.60%
$39.97
RMBL
+60.50%
$3.21
IREN
+8.04%
$64.58
ABAT
+34.34%
$9.06
ADD
-25.47%
$0.05
CORZ
+2.66%
$18.52
UUUU
+18.40%
$24.08
AAL
+1.51%
$11.69
RIG
+3.24%
$3.18
MARA
+9.43%
$20.40
EPWK
-11.00%
$0.08
NAKA
-4.05%
$0.83
UAMY
+37.67%
$16.80
PLTR
+0.84%
$176.92
SRM
+53.27%
$10.30
NOK
-1.79%
$5.22
IONQ
+18.72%
$83.88
PFE
+0.10%
$24.80
ADAP
-0.70%
$0.18
BMNR
+7.40%
$56.35
QUBT
+10.49%
$21.01
GDXD
-12.99%
$0.74
SNAP
+3.14%
$8.02
XCH
+119.76%
$1.81
CJET
-14.93%
$0.12
MRVL
-5.52%
$85.61
BULL
+1.62%
$11.58
NB
+3.81%
$10.78
CLSK
+2.49%
$19.76
MULN
-55.00%
$0.63
BINI
-55.00%
$0.63
CUTR
-10.19%
$0.09
PET
-59.91%
$0.04
AMZN
+1.81%
$220.30
AVGO
-5.90%
$324.63
NEHC
-8.12%
$2.60
WLGS
-5.57%
$0.04
BTG
+3.87%
$5.27
KDLY
-7.21%
$0.87
AMC
+0.68%
$2.95
ETWO
0.00%
$3.30
RF
+1.84%
$24.60
QSI
+23.35%
$2.06
HPE
+2.76%
$25.07
PMAX
+75.28%
$4.54
TMC
+18.40%
$10.52
ABEV
+1.42%
$2.14
KDP
+3.02%
$26.60
RGTZ
-42.68%
$10.66
T
-1.10%
$25.58
SMR
+15.95%
$45.50
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.